The life science software company iSentio AS opened office in Silicon Valley, US, last year as part of the company's strategy to grow globally. Their goal is to make their unique bacteria test, RipSeq, the leading DNA analysis tool for pathogen identification. Today more than 30 european hospitals are using the RipSeq-technology on a daily basis, and experience shows that this fast and precise technology makes a difference in the treatment of patients. Main focus this year is to raise further funding, the goal is 30-40 mill NOK in 2012 in order to accelerate the development of the company as well as grow sales and marketing. Read complete article in todays edition of Dagens Næringsliv
10.01.2012
iSentio is one of BTOs first start up companies, and has raised substantial funding from various finance sources. The leading norwegian business newspaper «Dagens Næringsliv» has published a 2-page article in todays edition, read complete article here (no longer available).